Download PDF
Semin Liver Dis 2020; 40(01): 049-060
DOI: 10.1055/s-0039-3401031
Review Article
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Role of Biomarkers in Guiding Cure of Viral Hepatitis B

Maria Buti   *
1   Liver Unit, Department of Internal Medicine, Hospital Universitari Vall d'Hebron, Barcelona, Spain
2   Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Instituto de Salud Carlos III, Madrid, Spain
,
Mar Riveiro-Barciela‡   *
1   Liver Unit, Department of Internal Medicine, Hospital Universitari Vall d'Hebron, Barcelona, Spain
2   Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Instituto de Salud Carlos III, Madrid, Spain
,
Francisco Rodríguez-Frías
2   Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Instituto de Salud Carlos III, Madrid, Spain
3   Liver Unit, Liver Diseases - Viral Hepatitis, Vall d'Hebron Institut of Research (VHIR), Hospital Universitari Vall d'Hebron, Barcelona, Spain
4   Liver Pathology Lab, Biochemistry and Microbiology Departments (Clinical Laboratories), Hospital Universitari Vall d'Hebron, Barcelona, Spain
,
David Tabernero
2   Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Instituto de Salud Carlos III, Madrid, Spain
3   Liver Unit, Liver Diseases - Viral Hepatitis, Vall d'Hebron Institut of Research (VHIR), Hospital Universitari Vall d'Hebron, Barcelona, Spain
,
Rafael Esteban
1   Liver Unit, Department of Internal Medicine, Hospital Universitari Vall d'Hebron, Barcelona, Spain
2   Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Instituto de Salud Carlos III, Madrid, Spain
› Author Affiliations
Further Information

Publication History

Publication Date:
05 December 2019 (online)

    Permissions and Reprints

Abstract

Chronic hepatitis B (CHB) virus infection is a global public health threat affecting approximately 257 million individuals worldwide. Hepatitis B surface antigen (HBsAg) loss has been the classic endpoint to define functional cure and decrease the large pool of individuals with CHB. Current treatments with nucleos(t)ide analogues persistently suppress hepatitis B virus (HBV) deoxyribonucleic acid in most CHB patients, but rarely achieve functional cure. New viral biomarkers, such as quantitative HBsAg, hepatitis B core-related antigen, and HBV ribonucleic acid, and combinations of these markers have the potential role of guiding HBV cure by enabling selection of the best candidates for therapy, identifying individuals with a higher likelihood of achieving HBsAg loss, and helping in the design of studies with new drugs. However, some of the assays used to analyze these markers require standardization and improvements in the level of detection. Analysis of host biomarkers to assess the host immune response to HBV is also important, as the natural course of CHB is determined by the interplay between viral replication and the immune response. These biomarkers are, however, in an early phase of development.

Keywords

hepatitis B virus - pregenomic RNA - HBcrAg - quantitative HBsAg - functional cure

* The two first authors contributed equally to the manuscript.


 

  • References

  • 1 Trépo C, Chan HL, Lok A. Hepatitis B virus infection. Lancet 2014; 384 (9959): 2053-2063
    CrossrefPubMedSearch in Google Scholar
  • 2 Fattovich G, Bortolotti F, Donato F. Natural history of chronic hepatitis B: special emphasis on disease progression and prognostic factors. J Hepatol 2008; 48 (02) 335-352
    CrossrefPubMedSearch in Google Scholar
  • 3 [Anonymous] European Association For The Study Of The Liver; European Organisation For Research And Treatment Of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 2012; 56 (04) 908-943
    CrossrefPubMedSearch in Google Scholar
  • 4 World Health Organization. Hepatitis B. Available at: https://www.who.int/news-room/fact-sheets/detail/hepatitis-b . Accessed July 18, 2019
    PubMed
  • 5 Testoni B, Levrero M, Zoulim F. Challenges to a cure for HBV infection. Semin Liver Dis 2017; 37 (03) 231-242
    Thieme ConnectPubMedSearch in Google Scholar
  • 6 Tong S, Revill P. Overview of hepatitis B viral replication and genetic variability. J Hepatol 2016; 64 (1, Suppl): S4-S16
    CrossrefPubMedSearch in Google Scholar
  • 7 Gerin JL, Ford EC, Purcell RH. Biochemical characterization of Australia antigen. Evidence for defective particles of hepatitis B virus. Am J Pathol 1975; 81 (03) 651-668
    PubMedSearch in Google Scholar
  • 8 Sakamoto Y, Yamada G, Mizuno M. , et al. Full and empty particles of hepatitis B virus in hepatocytes from patients with HBsAg-positive chronic active hepatitis. Lab Invest 1983; 48 (06) 678-682
    PubMedSearch in Google Scholar
  • 9 Hu J, Liu K. Complete and incomplete hepatitis B virus particles: formation, function, and application. Viruses 2017; 9 (03) 9
    CrossrefPubMedSearch in Google Scholar
  • 10 Seeger C, Mason WS. Molecular biology of hepatitis B virus infection. Virology 2015; ;479-480: 672-686
    PubMedSearch in Google Scholar
  • 11 Chou SF, Tsai ML, Huang JY, Chang YS, Shih C. The dual role of an ESCRT-0 component HGS in HBV transcription and naked capsid secretion. PLoS Pathog 2015; 11 (10) e1005123
    CrossrefPubMedSearch in Google Scholar
  • 12 Yang W, Summers J. Infection of ducklings with virus particles containing linear double-stranded duck hepatitis B virus DNA: illegitimate replication and reversion. J Virol 1998; 72 (11) 8710-8717
    CrossrefPubMedSearch in Google Scholar
  • 13 Kostyusheva A, Kostyushev D, Brezgin S, Volchkova E, Chulanov V. Clinical implications of hepatitis B virus RNA and covalently closed circular DNA in monitoring patients with chronic hepatitis B today with a gaze into the future: the field is unprepared for a sterilizing cure. Genes (Basel) 2018; 9 (10) 9
    PubMedSearch in Google Scholar
  • 14 Lok AS, Zoulim F, Dusheiko G, Ghany MG. Hepatitis B cure: from discovery to regulatory approval. Hepatology 2017; 66 (04) 1296-1313
    CrossrefPubMedSearch in Google Scholar
  • 15 Buti M, Tsai N, Petersen J. , et al. Seven-year efficacy and safety of treatment with tenofovir disoproxil fumarate for chronic hepatitis B virus infection. Dig Dis Sci 2015; 60 (05) 1457-1464
    CrossrefPubMedSearch in Google Scholar
  • 16 Buti M, Riveiro-Barciela M, Esteban R. Long-term safety and efficacy of nucleo(t)side analogue therapy in hepatitis B. Liver Int 2018; 38 (Suppl. 01) 84-89
    PubMedSearch in Google Scholar
  • 17 Marcellin P, Ahn SH, Ma X. , et al; Study 149 Investigators. Combination of tenofovir disoproxil fumarate and peginterferon α-2a increases loss of hepatitis B surface antigen in patients with chronic hepatitis B. Gastroenterology 2016; 150 (01) 134-144.e10
    CrossrefPubMedSearch in Google Scholar
  • 18 Marcellin P, Gane E, Buti M. , et al. Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study. Lancet 2013; 381 (9865): 468-475
    CrossrefPubMedSearch in Google Scholar
  • 19 Papatheodoridis G, Dalekos G, Sypsa V. , et al. PAGE-B predicts the risk of developing hepatocellular carcinoma in Caucasians with chronic hepatitis B on 5-year antiviral therapy. J Hepatol 2016; 64 (04) 800-806
    CrossrefPubMedSearch in Google Scholar
  • 20 Papatheodoridis GV, Idilman R, Dalekos GN. , et al. The risk of hepatocellular carcinoma decreases after the first 5 years of entecavir or tenofovir in Caucasians with chronic hepatitis B. Hepatology 2017; 66 (05) 1444-1453
    CrossrefPubMedSearch in Google Scholar
  • 21 Papatheodoridis GV, Sypsa V, Dalekos G. , et al. Eight-year survival in chronic hepatitis B patients under long-term entecavir or tenofovir therapy is similar to the general population. J Hepatol 2018; 68 (06) 1129-1136
    CrossrefPubMedSearch in Google Scholar
  • 22 [Anonymous] European Association for the Study of the Liver. Electronic address: easloffice@easloffice.eu; European Association for the Study of the Liver. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol 2017; 67 (02) 370-398
    CrossrefPubMedSearch in Google Scholar
  • 23 Perrillo RP, Martin P, Lok AS. Preventing hepatitis B reactivation due to immunosuppressive drug treatments. JAMA 2015; 313 (16) 1617-1618
    CrossrefPubMedSearch in Google Scholar
  • 24 Gill US, Kennedy PTF. Current therapeutic approaches for HBV infected patients. J Hepatol 2017; 67 (02) 412-414
    CrossrefPubMedSearch in Google Scholar
  • 25 Blumberg BS, Alter HJ, Visnich S. A “new” antigen in leukemia sera. JAMA 1965; 191: 541-546
    CrossrefPubMedSearch in Google Scholar
  • 26 Cornberg M, Wong VW, Locarnini S, Brunetto M, Janssen HLA, Chan HL. The role of quantitative hepatitis B surface antigen revisited. J Hepatol 2017; 66 (02) 398-411
    CrossrefPubMedSearch in Google Scholar
  • 27 Liao CC, Hsu CW, Gu PW, Yeh CT, Lin SM, Chiu CT. Comparison of the elecsys HBsAg II assay and the architect assay for quantification of hepatitis B surface antigen in chronic hepatitis B patients. Biomed J 2015; 38 (03) 250-256
    CrossrefPubMedSearch in Google Scholar
  • 28 Pfefferkorn M, Böhm S, Schott T. , et al. Quantification of large and middle proteins of hepatitis B virus surface antigen (HBsAg) as a novel tool for the identification of inactive HBV carriers. Gut 2018; 67 (11) 2045-2053
    CrossrefPubMedSearch in Google Scholar
  • 29 Peiffer KH, Kuhnhenn L, Jiang B. , et al. Divergent preS sequences in virion-associated hepatitis B virus genomes and subviral HBV surface antigen particles from HBV e antigen-negative patients. J Infect Dis 2018; 218 (01) 114-123
    CrossrefPubMedSearch in Google Scholar
  • 30 Jaroszewicz J, Calle Serrano B, Wursthorn K. , et al. Hepatitis B surface antigen (HBsAg) levels in the natural history of hepatitis B virus (HBV)-infection: a European perspective. J Hepatol 2010; 52 (04) 514-522
    CrossrefPubMedSearch in Google Scholar
  • 31 Chan HL, Wong VW, Wong GL, Tse CH, Chan HY, Sung JJ. A longitudinal study on the natural history of serum hepatitis B surface antigen changes in chronic hepatitis B. Hepatology 2010; 52 (04) 1232-1241
    CrossrefPubMedSearch in Google Scholar
  • 32 Thompson AJ, Nguyen T, Iser D. , et al. Serum hepatitis B surface antigen and hepatitis B e antigen titers: disease phase influences correlation with viral load and intrahepatic hepatitis B virus markers. Hepatology 2010; 51 (06) 1933-1944
    CrossrefPubMedSearch in Google Scholar
  • 33 Wooddell CI, Yuen MF, Chan HL. , et al. RNAi-based treatment of chronically infected patients and chimpanzees reveals that integrated hepatitis B virus DNA is a source of HBsAg. Sci Transl Med 2017; 9 (409) 9
    PubMedSearch in Google Scholar
  • 34 Manesis EK, Papatheodoridis GV, Tiniakos DG. , et al. Hepatitis B surface antigen: relation to hepatitis B replication parameters in HBeAg-negative chronic hepatitis B. J Hepatol 2011; 55 (01) 61-68
    CrossrefPubMedSearch in Google Scholar
  • 35 Brunetto MR, Marcellin P, Cherubini B. , et al. Response to peginterferon alfa-2a (40KD) in HBeAg-negative CHB: on-treatment kinetics of HBsAg serum levels vary by HBV genotype. J Hepatol 2013; 59 (06) 1153-1159
    CrossrefPubMedSearch in Google Scholar
  • 36 Riveiro-Barciela M, Bes M, Rodríguez-Frías F. , et al. Serum hepatitis B core-related antigen is more accurate than hepatitis B surface antigen to identify inactive carriers, regardless of hepatitis B virus genotype. Clin Microbiol Infect 2017; 23 (11) 860-867
    CrossrefPubMedSearch in Google Scholar
  • 37 Fung J, Lai CL, Young J. , et al. Quantitative hepatitis B surface antigen levels in patients with chronic hepatitis B after 2 years of entecavir treatment. Am J Gastroenterol 2011; 106 (10) 1766-1773
    CrossrefPubMedSearch in Google Scholar
  • 38 Marcellin P, Buti M, Krastev Z. , et al. Kinetics of hepatitis B surface antigen loss in patients with HBeAg-positive chronic hepatitis B treated with tenofovir disoproxil fumarate. J Hepatol 2014; 61 (06) 1228-1237
    CrossrefPubMedSearch in Google Scholar
  • 39 Chen CH, Chiu YC, Lu SN. , et al. Serum hepatitis B surface antigen levels predict treatment response to nucleos(t)ide analogues. World J Gastroenterol 2014; 20 (24) 7686-7695
    CrossrefPubMedSearch in Google Scholar
  • 40 Tseng TC, Liu CJ, Yang HC. , et al. Determinants of spontaneous surface antigen loss in hepatitis B e antigen-negative patients with a low viral load. Hepatology 2012; 55 (01) 68-76
    CrossrefPubMedSearch in Google Scholar
  • 41 Hadziyannis SJ, Sevastianos V, Rapti I, Vassilopoulos D, Hadziyannis E. Sustained responses and loss of HBsAg in HBeAg-negative patients with chronic hepatitis B who stop long-term treatment with adefovir. Gastroenterology 2012; 143 (03) 629-636.e1
    CrossrefPubMedSearch in Google Scholar
  • 42 Jeng WJ, Chen YC, Chien RN, Sheen IS, Liaw YF. Incidence and predictors of hepatitis B surface antigen seroclearance after cessation of nucleos(t)ide analogue therapy in hepatitis B e antigen-negative chronic hepatitis B. Hepatology 2018; 68 (02) 425-434
    CrossrefPubMedSearch in Google Scholar
  • 43 Zoulim F, Yogaratnam J, Vandenbossche JJ. , et al. Safety, pharmacokinetics and antiviral activity of a novel hepatitis B virus (HBV) capsid assembly modulator, JNJ-56136379, in patients with chronic hepatitis B (CHB). Hepatology 2018; 68: 47A
    PubMedSearch in Google Scholar
  • 44 Ma X, Lalezari J, Nguyen T. , et al. Interim safety and efficacy results of the ABI-H0731 phase 2a program exploring the combination of ABI-H0731 with Nuc therapy in treatment-naive and treatment-suppressed chronic hepatitis B patients. J Hepatol 2019; 70: e130-e131
    PubMedSearch in Google Scholar
  • 45 Yuen MF, Locarnini S, Lim TH. , et al. Short term RNA interference therapy in chronic hepatitis B using JNJ-3989 brings majority of patients to HBsAg < 100 IU/ml threshold. J Hepatol 2019; 70: e51-e52
    PubMedSearch in Google Scholar
  • 46 Vaillant A. REP 2139: antiviral mechanisms and applications in achieving functional control of HBV and HDV infection. ACS Infect Dis 2019; 5 (05) 675-687
    CrossrefPubMedSearch in Google Scholar
  • 47 Boni C, Vecchi A, Rossi M. , et al. TLR7 agonist increases responses of hepatitis B virus-specific T cells and natural killer cells in patients with chronic hepatitis B treated with nucleos(t)ide analogues. Gastroenterology 2018; 154 (06) 1764-1777.e7
    CrossrefPubMedSearch in Google Scholar
  • 48 Boni C, Janssen HLA, Rossi M. , et al. Combined GS-4774 and tenofovir therapy can improve HBV-specific T-cell responses in patients with chronic hepatitis. Gastroenterology 2019; 157 (01) 227-241.e7
    CrossrefPubMedSearch in Google Scholar
  • 49 Terrault NA, Bzowej NH, Chang KM, Hwang JP, Jonas MM, Murad MH. ; American Association for the Study of Liver Diseases. AASLD guidelines for treatment of chronic hepatitis B. Hepatology 2016; 63 (01) 261-283
    CrossrefPubMedSearch in Google Scholar
  • 50 Burdette D, Cathcart A, Shauf A. , et al. Evidence for the presence of infectious virus in the serum from chronic hepatitis B patients suppressed on nucleos (t)ide therapy with detectable but not quantifiable HBV DNA. J Hepatol 2019; 70: e95
    PubMedSearch in Google Scholar
  • 51 Candotti D, Assennato SM, Laperche S, Allain JP, Levicnik-Stezinar S. Multiple HBV transfusion transmissions from undetected occult infections: revising the minimal infectious dose. Gut 2019; 68 (02) 313-321
    CrossrefPubMedSearch in Google Scholar
  • 52 Iloeje UH, Yang HI, Su J, Jen CL, You SL, Chen CJ. ; Risk Evaluation of Viral Load Elevation and Associated Liver Disease/Cancer-In HBV (the REVEAL-HBV) Study Group. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology 2006; 130 (03) 678-686
    CrossrefPubMedSearch in Google Scholar
  • 53 Liu CJ, Chen BF, Chen PJ. , et al. Role of hepatitis B viral load and basal core promoter mutation in hepatocellular carcinoma in hepatitis B carriers. J Infect Dis 2006; 193 (09) 1258-1265
    CrossrefPubMedSearch in Google Scholar
  • 54 Chan HL, Sung JJ. Hepatocellular carcinoma and hepatitis B virus. Semin Liver Dis 2006; 26 (02) 153-161
    Thieme ConnectPubMedSearch in Google Scholar
  • 55 Milich D, Liang TJ. Exploring the biological basis of hepatitis B e antigen in hepatitis B virus infection. Hepatology 2003; 38 (05) 1075-1086
    CrossrefPubMedSearch in Google Scholar
  • 56 Wong D, Littlejohn M, Yuen L. , et al. HBeAg levels at week 24 predict response to 8 years of tenofovir in HBeAg-positive chronic hepatitis B patients. Aliment Pharmacol Ther 2018; 47 (01) 114-122
    CrossrefPubMedSearch in Google Scholar
  • 57 Bayliss J, Yuen L, Rosenberg G. , et al. Deep sequencing shows that HBV basal core promoter and precore variants reduce the likelihood of HBsAg loss following tenofovir disoproxil fumarate therapy in HBeAg-positive chronic hepatitis B. Gut 2017; 66 (11) 2013-2023
    CrossrefPubMedSearch in Google Scholar
  • 58 Milich DR, Chen M, Schödel F, Peterson DL, Jones JE, Hughes JL. Role of B cells in antigen presentation of the hepatitis B core. Proc Natl Acad Sci U S A 1997; 94 (26) 14648-14653
    CrossrefPubMedSearch in Google Scholar
  • 59 Yang HI, Yuen MF, Chan HL. , et al; REACH-B Working Group. Risk estimation for hepatocellular carcinoma in chronic hepatitis B (REACH-B): development and validation of a predictive score. Lancet Oncol 2011; 12 (06) 568-574
    CrossrefPubMedSearch in Google Scholar
  • 60 Rehermann B, Ferrari C, Pasquinelli C, Chisari FV. The hepatitis B virus persists for decades after patients' recovery from acute viral hepatitis despite active maintenance of a cytotoxic T-lymphocyte response. Nat Med 1996; 2 (10) 1104-1108
    CrossrefPubMedSearch in Google Scholar
  • 61 Lebossé F, Testoni B, Fresquet J. , et al. Intrahepatic innate immune response pathways are downregulated in untreated chronic hepatitis B. J Hepatol 2017; 66 (05) 897-909
    CrossrefPubMedSearch in Google Scholar
  • 62 Xia Y, Stadler D, Ko C, Protzer U. Analyses of HBV cccDNA quantification and modification. Methods Mol Biol 2017; 1540: 59-72
    PubMedSearch in Google Scholar
  • 63 Huang JT, Yang Y, Hu YM. , et al. A highly sensitive and robust method for hepatitis B virus covalently closed circular DNA detection in single cells and serum. J Mol Diagn 2018; 20 (03) 334-343
    CrossrefPubMedSearch in Google Scholar
  • 64 Testoni B, Lebossé F, Scholtes C. , et al. Serum hepatitis B core-related antigen (HBcrAg) correlates with covalently closed circular DNA transcriptional activity in chronic hepatitis B patients. J Hepatol 2019; 70 (04) 615-625
    CrossrefPubMedSearch in Google Scholar
  • 65 Chen EQ, Feng S, Wang ML. , et al. Serum hepatitis B core-related antigen is a satisfactory surrogate marker of intrahepatic covalently closed circular DNA in chronic hepatitis B. Sci Rep 2017; 7 (01) 173
    CrossrefPubMedSearch in Google Scholar
  • 66 Boyd A, Lacombe K, Lavocat F. , et al. Decay of ccc-DNA marks persistence of intrahepatic viral DNA synthesis under tenofovir in HIV-HBV co-infected patients. J Hepatol 2016; 65 (04) 683-691
    CrossrefPubMedSearch in Google Scholar
  • 67 Werle-Lapostolle B, Bowden S, Locarnini S. , et al. Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy. Gastroenterology 2004; 126 (07) 1750-1758
    CrossrefPubMedSearch in Google Scholar
  • 68 Lai CL, Wong D, Ip P. , et al. Reduction of covalently closed circular DNA with long-term nucleos(t)ide analogue treatment in chronic hepatitis B. J Hepatol 2017; 66 (02) 275-281
    CrossrefPubMedSearch in Google Scholar
  • 69 Lam AM, Ren S, Espiritu C. , et al. Hepatitis B virus capsid assembly modulators, but not nucleoside analogs, inhibit the production of extracellular pregenomic RNA and spliced RNA variants. Antimicrob Agents Chemother 2017; 61 (08) 61
    PubMedSearch in Google Scholar
  • 70 Wang J, Shen T, Huang X. , et al. Serum hepatitis B virus RNA is encapsidated pregenome RNA that may be associated with persistence of viral infection and rebound. J Hepatol 2016; 65 (04) 700-710
    CrossrefPubMedSearch in Google Scholar
  • 71 Rokuhara A, Matsumoto A, Tanaka E. , et al. Hepatitis B virus RNA is measurable in serum and can be a new marker for monitoring lamivudine therapy. J Gastroenterol 2006; 41 (08) 785-790
    CrossrefPubMedSearch in Google Scholar
  • 72 van Bömmel F, Bartens A, Mysickova A. , et al. Serum hepatitis B virus RNA levels as an early predictor of hepatitis B envelope antigen seroconversion during treatment with polymerase inhibitors. Hepatology 2015; 61 (01) 66-76
    CrossrefPubMedSearch in Google Scholar
  • 73 Butler EK, Gersch J, McNamara A. , et al. Hepatitis B virus serum DNA and RNA levels in nucleos(t)ide analog-treated or untreated patients during chronic and acute infection. Hepatology 2018; 68 (06) 2106-2117
    CrossrefPubMedSearch in Google Scholar
  • 74 Prakash K, Rydell GE, Larsson SB. , et al. High serum levels of pregenomic RNA reflect frequently failing reverse transcription in hepatitis B virus particles. Virol J 2018; 15 (01) 86
    CrossrefPubMedSearch in Google Scholar
  • 75 Huang YW, Takahashi S, Tsuge M. , et al. On-treatment low serum HBV RNA level predicts initial virological response in chronic hepatitis B patients receiving nucleoside analogue therapy. Antivir Ther 2015; 20 (04) 369-375
    PubMedSearch in Google Scholar
  • 76 Liu S, Zhou B, Valdes JD, Sun J, Guo H. Serum hepatitis B virus RNA: a new potential biomarker for chronic hepatitis B virus infection. Hepatology 2019; 69 (04) 1816-1827
    CrossrefPubMedSearch in Google Scholar
  • 77 van Campenhout MJH, van Bömmel F, Pfefferkorn M. , et al. Host and viral factors associated with serum hepatitis B virus RNA levels among patients in need for treatment. Hepatology 2018; 68 (03) 839-847
    CrossrefPubMedSearch in Google Scholar
  • 78 Wang J, Yu Y, Li G. , et al. Relationship between serum HBV-RNA levels and intrahepatic viral as well as histologic activity markers in entecavir-treated patients. J Hepatol 2017; •••: S0168-8278(17)32261-4 . Doi: 10.1016/j.jhep.2017.08.021
    PubMedSearch in Google Scholar
  • 79 Yuen MF, Chen CY, Liu CJ. , et al. Ascending dose cohort study of inarigivir - a novel RIG I agonist in chronic HBV patients: final results of the ACHIEVE trial. J Hepatol 2019; 70: e47-e48
    PubMedSearch in Google Scholar
  • 80 Huang H, Wang J, Li W. , et al. Serum HBV DNA plus RNA shows superiority in reflecting the activity of intrahepatic cccDNA in treatment-naïve HBV-infected individuals. J Clin Virol 2018; ;99-100: 71-78
    PubMedSearch in Google Scholar
  • 81 Yu X, Yu D, Chen P. , et al. Dynamic changes of serum HBV pgRNA levels in patients with chronic hepatitis B treated with entecavir or peg-interferon. J Hepatol 2019; 70: e490
    CrossrefPubMedSearch in Google Scholar
  • 82 Breitkreutz R, Zhang W, Lee M. , et al. Hepatitis B virus nucleic acids circulating in the blood: distinct patterns in HBs carriers with hepatocellular carcinoma. Ann N Y Acad Sci 2001; 945: 195-206
    PubMedSearch in Google Scholar
  • 83 Gao Y, Li Y, Meng Q. , et al. Serum hepatitis B virus DNA, RNA, and HBsAg: which correlated better with intrahepatic covalently closed circular DNA before and after nucleos(t)ide analogue treatment?. J Clin Microbiol 2017; 55 (10) 2972-2982
    CrossrefPubMedSearch in Google Scholar
  • 84 Wang J, Yu Y, Li G. , et al. Natural history of serum HBV-RNA in chronic HBV infection. J Viral Hepat 2018; 25 (09) 1038-1047
    CrossrefPubMedSearch in Google Scholar
  • 85 van Bömmel F, Deichsel D, Loglio A. , et al. HBV RNA can be detected more frequently than HBcrAg but decreases during long term treatment with nucleos (t)ide analogues up to 14 years in patients with HBeAg negative chronic hepatitis B. J Hepatol 2019; 70: e487
    PubMedSearch in Google Scholar
  • 86 Carey I, Gersch J, Bruce M. , et al. The markers of HBV transcriptional activity-HBcrAg and pregenomic HBV DNA during antiviral therapy with nucleos (t)ide analogue help to predict optimal timing of therapy withdrawal. J Hepatol 2019; 70: e33-e34
    PubMedSearch in Google Scholar
  • 87 Shah PA, Rajab I, Choudhry S. , et al. The application of novel HBV pgRNA assay to predict HBeAg clearance on long-term nucleos (t)ide analogues. J Hepatol 2019; 70: e262-e263
    PubMedSearch in Google Scholar
  • 88 Jansen L, Kootstra NA, van Dort KA, Takkenberg RB, Reesink HW, Zaaijer HL. Hepatitis B virus pregenomic RNA is present in virions in plasma and is associated with a response to pegylated interferon alfa-2a and nucleos(t)ide analogues. J Infect Dis 2016; 213 (02) 224-232
    CrossrefPubMedSearch in Google Scholar
  • 89 Jia W, Zhu MQ, Qi X. , et al. Serum hepatitis B virus RNA levels as a predictor of HBeAg seroconversion during treatment with peginterferon alfa-2a. Virol J 2019; 16 (01) 61
    CrossrefPubMedSearch in Google Scholar
  • 90 Gane E, Yuen MF, Bo Q. , et al. RO7049389, a core protein allosteric modulator, demonstrates robust decline in HBV DNA and HBV RNA in chronic HBV infected patients. J Hepatol 2019; 70: e491
    PubMedSearch in Google Scholar
  • 91 Kimura T, Rokuhara A, Sakamoto Y. , et al. Sensitive enzyme immunoassay for hepatitis B virus core-related antigens and their correlation to virus load. J Clin Microbiol 2002; 40 (02) 439-445
    CrossrefPubMedSearch in Google Scholar
  • 92 Lam YF, Seto WK, Wong D. , et al. Seven-year treatment outcome of entecavir in a real-world cohort: effects on clinical parameters, HBsAg and HBcrAg levels. Clin Transl Gastroenterol 2017; 8 (10) e125
    CrossrefPubMedSearch in Google Scholar
  • 93 Liao H, Liu Y, Li X. , et al. Monitoring of serum HBV RNA, HBcrAg, HBsAg and anti-HBc levels in patients during long-term nucleoside/nucleotide analogue therapy. Antivir Ther 2019; 24 (02) 105-115
    PubMedSearch in Google Scholar
  • 94 Jung KS, Park JY, Chon YE. , et al. Clinical outcomes and predictors for relapse after cessation of oral antiviral treatment in chronic hepatitis B patients. J Gastroenterol 2016; 51 (08) 830-839
    CrossrefPubMedSearch in Google Scholar
  • 95 Matsumoto A, Tanaka E, Minami M. , et al. Low serum level of hepatitis B core-related antigen indicates unlikely reactivation of hepatitis after cessation of lamivudine therapy. Hepatol Res 2007; 37 (08) 661-666
    CrossrefPubMedSearch in Google Scholar
  • 96 Hsu YC, Nguyen MH, Mo LR. , et al. Combining hepatitis B core-related and surface antigens at end of nucleos(t)ide analogue treatment to predict off-therapy relapse risk. Aliment Pharmacol Ther 2019; 49 (01) 107-115
    CrossrefPubMedSearch in Google Scholar
  • 97 Matsumoto A, Yatsuhashi H, Nagaoka S. , et al. Factors associated with the effect of interferon-α sequential therapy in order to discontinue nucleoside/nucleotide analog treatment in patients with chronic hepatitis B. Hepatol Res 2015; 45 (12) 1195-1202
    CrossrefPubMedSearch in Google Scholar
  • 98 Martinot-Peignoux M, Lapalus M, Maylin S. , et al. Baseline HBsAg and HBcrAg titres allow peginterferon-based ‘precision medicine’ in HBeAg-negative chronic hepatitis B patients. J Viral Hepat 2016; 23 (11) 905-911
    CrossrefPubMedSearch in Google Scholar
  • 99 Corcuera A, Stolle K, Hillmer S. , et al. Novel non-heteroarylpyrimidine (HAP) capsid assembly modifiers have a different mode of action from HAPs in vitro. Antiviral Res 2018; 158: 135-142
    CrossrefPubMedSearch in Google Scholar
  • 100 Yuen MY, Chan HLY, Liu K. , et al. Differential reductions in viral antigens expressed from cccDNA vs integrated DNA in treatment naïve HBeAg positive and negative patients with chronic HBV after RNA interference therapy with ARC-520. J Hepatol 2016; 64: S390-S391
    PubMedSearch in Google Scholar
  • 101 Inoue T, Tanaka Y. The role of hepatitis B core-related antigen. Genes (Basel) 2019; 10 (05) 10
    PubMedSearch in Google Scholar
  • 102 Sonneveld MJ, Brouwer WP, Chan HL. , et al. Optimisation of the use of APRI and FIB-4 to rule out cirrhosis in patients with chronic hepatitis B: results from the SONIC-B study. Lancet Gastroenterol Hepatol 2019; 4 (07) 538-544
    PubMedSearch in Google Scholar
  • 103 Huang H, Sun Z, Pan H. , et al. Serum metabolomic signatures discriminate early liver inflammation and fibrosis stages in patients with chronic hepatitis B. Sci Rep 2016; 6: 30853
    CrossrefPubMedSearch in Google Scholar
  • 104 Zhang Z, Zhang JY, Wang LF, Wang FS. Immunopathogenesis and prognostic immune markers of chronic hepatitis B virus infection. J Gastroenterol Hepatol 2012; 27 (02) 223-230
    CrossrefPubMedSearch in Google Scholar
  • 105 He D, Li M, Guo S. , et al. Expression pattern of serum cytokines in hepatitis B virus infected patients with persistently normal alanine aminotransferase levels. J Clin Immunol 2013; 33 (07) 1240-1249
    CrossrefPubMedSearch in Google Scholar
  • 106 Rivino L, Le Bert N, Gill US. , et al. Hepatitis B virus-specific T cells associate with viral control upon nucleos(t)ide-analogue therapy discontinuation. J Clin Invest 2018; 128 (02) 668-681
    CrossrefPubMedSearch in Google Scholar
  • 107 Sung PS, Park DJ, Kim JH. , et al. Ex vivo detection and characterization of hepatitis B virus-specific CD8+ T cells in patients considered immune tolerant. Front Immunol 2019; 10: 1319
    CrossrefPubMedSearch in Google Scholar
  • 108 Hoofnagle JH, Seeff LB, Bales ZB, Zimmerman HJ. Type B hepatitis after transfusion with blood containing antibody to hepatitis B core antigen. N Engl J Med 1978; 298 (25) 1379-1383
    CrossrefPubMedSearch in Google Scholar
  • 109 Caviglia G, Tandoi F, Troshina G. , et al. Characterization of a novel chemiluminescent enzyme immunoassay for the quantitation of antibodies to hepatitis B core antigen class IgG and correlation with intrahepatic HBV covalently-closed-circular DNA. J Hepatol 2019; 70: e254-e255
    PubMedSearch in Google Scholar
  • 110 Song LW, Liu PG, Liu CJ. , et al. Quantitative hepatitis B core antibody levels in the natural history of hepatitis B virus infection. Clin Microbiol Infect 2015; 21 (02) 197-203
    CrossrefPubMedSearch in Google Scholar
  • 111 Yuan Q, Song LW, Cavallone D. , et al. Total hepatitis B core antigen antibody, a quantitative non-invasive marker of hepatitis B virus induced liver disease. PLoS One 2015; 10 (06) e0130209
    CrossrefPubMedSearch in Google Scholar
  • 112 Loglio A, Facchetti F, Orsini C. , et al. Quantitative antibodies against hepatitis B core antigen differ in NUC suppressed Caucasian HbeAG-negative patients compared to patients who achieved either “NUC induced” or “spontaneous” functional cure of HBV. J Hepatol 2019; 70: e33
    PubMedSearch in Google Scholar
  • 113 Yang HC, Tsou HH, Pei SN. , et al; Taiwan Cooperative Oncology Group. Quantification of HBV core antibodies may help predict HBV reactivation in patients with lymphoma and resolved HBV infection. J Hepatol 2018; 69 (02) 286-292
    CrossrefPubMedSearch in Google Scholar
  • 114 Caviglia GP, Abate ML, Tandoi F. , et al. Quantitation of HBV cccDNA in anti-HBc-positive liver donors by droplet digital PCR: a new tool to detect occult infection. J Hepatol 2018; 69 (02) 301-307
    CrossrefPubMedSearch in Google Scholar
  • 115 Yuan Q, Song LW, Liu CJ. , et al. Quantitative hepatitis B core antibody level may help predict treatment response in chronic hepatitis B patients. Gut 2013; 62 (01) 182-184
    PubMedSearch in Google Scholar
  • 116 Chi H, Li Z, Hansen BE. , et al. Serum level of antibodies against hepatitis B core protein is associated with clinical relapse after discontinuation of nucleos(t)ide analogue therapy. Clin Gastroenterol Hepatol 2019; 17 (01) 182-191.e1
    CrossrefPubMedSearch in Google Scholar
  • 117 Xu JH, Song LW, Li N. , et al. Baseline hepatitis B core antibody predicts treatment response in chronic hepatitis B patients receiving long-term entecavir. J Viral Hepat 2017; 24 (02) 148-154
    CrossrefPubMedSearch in Google Scholar
  • 118 Tseng TC, Liu CJ, Yang HC. , et al. High levels of hepatitis B surface antigen increase risk of hepatocellular carcinoma in patients with low HBV load. Gastroenterology 2012; 142 (05) 1140-1149.e3 , quiz e13–e14
    CrossrefPubMedSearch in Google Scholar
  • 119 Hu HH, Liu J, Lin YL. , et al; REVEAL-HBV Study Group. The rs2296651 (S267F) variant on NTCP (SLC10A1) is inversely associated with chronic hepatitis B and progression to cirrhosis and hepatocellular carcinoma in patients with chronic hepatitis B. Gut 2016; 65 (09) 1514-1521
    CrossrefPubMedSearch in Google Scholar
  • 120 Binh MT, Hoan NX, Van Tong H. , et al. NTCP S267F variant associates with decreased susceptibility to HBV and HDV infection and decelerated progression of related liver diseases. Int J Infect Dis 2019; 80: 147-152
    CrossrefPubMedSearch in Google Scholar
  • 121 Lee HW, Park HJ, Jin B. , et al. Effect of S267F variant of NTCP on the patients with chronic hepatitis B. Sci Rep 2017; 7 (01) 17634
    CrossrefPubMedSearch in Google Scholar
  • 122 Fukano K, Tsukuda S, Watashi K, Wakita T. Concept of viral inhibitors via NTCP. Semin Liver Dis 2019; 39 (01) 78-85
    Thieme ConnectPubMedSearch in Google Scholar
  • 123 Blank A, Markert C, Hohmann N. , et al. First-in-human application of the novel hepatitis B and hepatitis D virus entry inhibitor myrcludex B. J Hepatol 2016; 65 (03) 483-489
    CrossrefPubMedSearch in Google Scholar
  • 124 Eslam M, Hashem AM, Leung R. , et al; International Hepatitis C Genetics Consortium (IHCGC). Interferon-λ rs12979860 genotype and liver fibrosis in viral and non-viral chronic liver disease. Nat Commun 2015; 6: 6422
    CrossrefPubMedSearch in Google Scholar
  • 125 Eslam M, Hashem AM, Romero-Gomez M. , et al; International Liver Disease Genetics Consortium (ILDGC). FibroGENE: a gene-based model for staging liver fibrosis. J Hepatol 2016; 64 (02) 390-398
    CrossrefPubMedSearch in Google Scholar
  • 126 Cheng HR, Liu CJ, Tseng TC. , et al. Host genetic factors affecting spontaneous HBsAg seroclearance in chronic hepatitis B patients. PLoS One 2013; 8 (01) e53008
    CrossrefPubMedSearch in Google Scholar
  • 127 Wu H, Zhao G, Qian F. , et al. Association of IL28B polymorphisms with peginterferon treatment response in Chinese Han patients with HBeAg-positive chronic hepatitis B. Liver Int 2015; 35 (02) 473-481
    CrossrefPubMedSearch in Google Scholar
  • 128 Lampertico P, Viganò M, Cheroni C. , et al. IL28B polymorphisms predict interferon-related hepatitis B surface antigen seroclearance in genotype D hepatitis B e antigen-negative patients with chronic hepatitis B. Hepatology 2013; 57 (03) 890-896
    CrossrefPubMedSearch in Google Scholar
  • 129 Cheng L, Sun X, Tan S. , et al. Effect of HLA-DP and IL28B gene polymorphisms on response to interferon treatment in hepatitis B e-antigen seropositive chronic hepatitis B patients. Hepatol Res 2014; 44 (09) 1000-1007
    CrossrefPubMedSearch in Google Scholar
  • 130 Kakizaki M, Yamamoto Y, Yabuta S, Kurosaki N, Kagawa T, Kotani A. The immunological function of extracellular vesicles in hepatitis B virus-infected hepatocytes. PLoS One 2018; 13 (12) e0205886
    CrossrefPubMedSearch in Google Scholar
  • 131 Yang Y, Han Q, Hou Z, Zhang C, Tian Z, Zhang J. Exosomes mediate hepatitis B virus (HBV) transmission and NK-cell dysfunction. Cell Mol Immunol 2017; 14 (05) 465-475
    PubMedSearch in Google Scholar
  • 132 Su TH, Liu CJ, Tseng TC. , et al. Longitudinal change of HBsAg in HBeAg-negative patients with genotype B or C infection. PLoS One 2013; 8 (02) e55916
    CrossrefPubMedSearch in Google Scholar
  • 133 Seto WK, Wong DK, Fung J. , et al. A large case-control study on the predictability of hepatitis B surface antigen levels three years before hepatitis B surface antigen seroclearance. Hepatology 2012; 56 (03) 812-819
    CrossrefPubMedSearch in Google Scholar
  • 134 Brunetto MR, Oliveri F, Colombatto P. , et al. Hepatitis B surface antigen serum levels help to distinguish active from inactive hepatitis B virus genotype D carriers. Gastroenterology 2010; 139 (02) 483-490
    CrossrefPubMedSearch in Google Scholar
  • 135 Martinot-Peignoux M, Lapalus M, Laouénan C. , et al. Prediction of disease reactivation in asymptomatic hepatitis B e antigen-negative chronic hepatitis B patients using baseline serum measurements of HBsAg and HBV-DNA. J Clin Virol 2013; 58 (02) 401-407
    CrossrefPubMedSearch in Google Scholar
  • 136 Maasoumy B, Wiegand SB, Jaroszewicz J. , et al. Hepatitis B core-related antigen (HBcrAg) levels in the natural history of hepatitis B virus infection in a large European cohort predominantly infected with genotypes A and D. Clin Microbiol Infect 2015; 21 (06) 606.e1-606.e10
    CrossrefPubMedSearch in Google Scholar
  • 137 Caballero A, Tabernero D, Buti M, Rodriguez-Frias F. Hepatitis B virus: the challenge of an ancient virus with multiple faces and a remarkable replication strategy. Antiviral Res 2018; 158: 34-44
    CrossrefPubMedSearch in Google Scholar